The idea of using debt to support businesses in healthcare and life sciences tends to be viewed warily and with good reason. At MidAmerica Healthcare Venture Forum this week, GE Capital senior vice president in life sciences Joe Hammer offered up some helpful insights on the different kinds of debt available to biotech and medical device companies, from pre-revenue stage companies to more mature businesses.
